Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. S...
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Study on Human Bioequivalence of Triprerelin Acetate for Injection
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 120
- Registration Number
- NCT06683066
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer
- Conditions
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-09-03
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 184
- Registration Number
- NCT06581679
- Locations
- 🇪🇬
Zagazig university, Zagazig, Ash Sharqia Governorate, Egypt
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Santa Chiara Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06473259
- Locations
- 🇮🇹
Azienda Ospedaliera San Luigi, Orbassano, Torino, Italy
🇮🇹Istituto Oncologico Veneto, Padova, Italy
🇮🇹Santa Chiara Hospital, Trento, Italy
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 48
- Registration Number
- NCT05982093
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 387
- Registration Number
- NCT05972902
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 300
- Registration Number
- NCT05800197
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Regina Elena Cancer Institute
- Target Recruit Count
- 146
- Registration Number
- NCT05557604
- Locations
- 🇮🇹
Ifo Regina elena, Rome, Lazio, Italy
🇮🇹Regina Elena National Cancer Institute, Rome, Italy
🇮🇹ifo Regina Elena, Rome, RM, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.